The biggest story in Greater Philadelphia this week isn’t any one announcement, it’s what they reveal together. Rare disease innovators are moving programs into the clinic, manufacturers are expanding their footprint, employers are investing in talent, experienced leaders are stepping into key roles, and the state is putting new resources behind company creation. Individually, they’re noteworthy.
Pennsylvania’s $125 million Innovate in PA 2.0 initiative is designed to help more discoveries become companies, while clinical milestones from Medicus Pharma and Inhibikase Therapeutics highlight the region’s strength in tackling high-need diseases. Minaris is reinforcing Philadelphia’s position as a cell and gene therapy hub through both digital manufacturing expansion and a major hiring push.
Greater Philadelphia’s life sciences community was also well represented among this year’s Best Places to Work honorees, while a wave of leadership appointments underscores the depth of talent choosing to build in the region. Isn’t just generating innovation, it’s building the ecosystem that ensures it can grow.
Financial
Tracking the capital moving through Greater Philadelphia— funding rounds, M&A activity, and investment trends shaping Philadelphia, Southern New Jersey, and Delaware’s life sciences companies.
Synaptiq Therapeutics Launches with Acquisition of Clinical-Stage SYN-001 Program
Synaptiq Therapeutics has launched in Iceland and Philadelphia with the acquisition of SYN-001, an FDA orphan-designated small molecule targeting neuropsychiatric symptoms of 22q11.2 Deletion Syndrome, a rare genetic disorder affecting ~65,000 Americans. Backed by Arctic Therapeutics, Sanos Group, and AxUM Securities, the company is heading into Phase IIb trials toward what could be the first approved therapy for the condition. Read More >
Lipid nanoparticle startup Nava emerges with $89M to target T cells and kidney
Nava Therapeutics has emerged from stealth with $89M to build lipid nanoparticles that bypass the liver and reach immune cells and kidneys instead. Its lead program, NT-001, aims to generate CAR-T cells directly inside the body — skipping the weeks-long ex vivo manufacturing process , with backing from RA Capital, Leaps by Bayer, and PureTech Health. Read More >
Johnson & Johnson Backs In Vivo CAR-T With a Three-Part Deal for Sail Biomedicines
Johnson & Johnson Innovative Medicine is betting big on in vivo CAR-T, striking a deal with Flagship Pioneering’s Sail Biomedicines worth up to $3.5B, including $785M upfront and an exclusive option to acquire the company outright for $2.58B. Sail’s “Endless RNA” platform aims to reprogram a patient’s own immune cells inside the body, skipping traditional CAR-T’s costly extract-engineer-reinfuse process, with J&J targeting autoimmune disease as the first frontier. Read More >
People
Who we’re buzzing about this week — the leadership moves, board appointments, and rising names shaping the region’s life sciences community.
Brendan O’Hara Joins Independence Blue Cross in Corporate Development and Strategic Investments
Philadelphia-based Independence Blue Cross, the region’s largest health insurer, has brought on Brendan O’Hara to lead Corporate Development and Strategic Investments. O’Hara joins after nearly five years at Amneal Pharmaceuticals, where he worked on oncology biosimilars, specialty pharma licensing deals, and GLP-1 supply contracts, dealmaking experience he’ll now apply from the payer side to questions of access, affordability, and capital deployment. Read More >
Sayali Saykhedkar Joins Bristol Myers Squibb as Associate Director, Bioanalysis and Companion Diagnostics
Sayali Saykhedkar has joined Bristol Myers Squibb’s growing bioanalysis and diagnostics organization, bringing over a decade of cross-modality bioanalytical experience spanning gene therapy, ADCs, and biologics. She joins after five years at Spark Therapeutics, where she led regulated bioanalysis for rare and neurodegenerative disease gene therapy programs, and will now support BMS’s 50-compound pipeline across more than 40 disease areas. Read More >
Bryan J. Hansen, Ph.D., Rejoins Johnson & Johnson as Senior Director, External Scientific Innovation
Bryan J. Hansen, Ph.D. has rejoined Johnson & Johnson Innovative Medicine as Senior Director, External Scientific Innovation, leading the company’s incubation portfolio across East North America. The neuroscientist returns after nearly four years at J&J and six-plus years at Merck, bringing deep expertise in digital biomarkers and AI-driven CNS drug development to scout early-stage science in oncology, immunology, and neuroscience. Read More >
Workforce
The hiring activity, team expansions, and talent trends driving growth across Philadelphia, New Jersey, and Delaware life sciences and biotech employers.
Celebrating Philly’s Life Sciences Leaders Among the 2026 Best Places to Work
Greater Philadelphia’s life sciences sector made a strong showing among this year’s Philadelphia Business Journal Best Places to Work finalists, with companies spanning biotech and pharma, clinical research and CROs, lab design and engineering, and healthcare-focused data and marketing firms all making the list. The breadth of finalists underscores just how deep the region’s life sciences bench has become. Read More >
ChristianaCare’s Cawley Center for Translational Cancer Research launched a summer internship program
ChristianaCare’s Cawley Center for Translational Cancer Research has launched the first internship program at a community cancer center’s organoid core, a specialized lab where researchers grow tumor-derived models to identify personalized cancer therapies. Two Delaware Technical Community College undergraduates are the program’s inaugural interns, gaining hands-on lab experience alongside direct exposure to clinical tumor board discussions. Read More >
Who’s hiring?!
A global contract development and manufacturing organization (CDMO) specializing in cell and gene therapies, Minaris is dedicated to helping innovators succeed, from early-stage development through commercial launch , with end-to-end expertise in GMP manufacturing, biosafety, and analytical testing of biologics.
With a state-of-the-art manufacturing facility in the Greater Philadelphia region, Minaris is strengthening one of the world’s leading cell and gene therapy hubs by bringing together scientists, engineers, quality experts, and problem solvers dedicated to helping life-changing therapies reach patients faster and more reliably.
They are currently hiring across 90+ roles in the Greater Philadelphia region. Apply Now >
Other employers and available roles we’re paying attention to this week:
- QIAGEN (Philadelphia, PA) is hiring a Genomics Sales Specialist, Quantabio (Northeast Region) | Apply Now >
- Pharmaron (Exton, PA) is hiring a Scientist II, Discovery DMPK | Apply Now >
- Charles River Laboratories (Wayne, PA) is hiring a Technician, Molecular Biology | Apply Now >
- United Therapeutics (Philadelphia, PA) is hiring a Therapy Access Manager – Mid-Atlantic | Apply Now >
Clinical + Commercial
The latest clinical trial progress, regulatory milestones, and commercial launches from companies advancing science from the lab to the market across Greater Philadelphia.
Medicus Pharma Receives FDA “Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin Syndrome
Medicus Pharma has cleared FDA authorization to launch a Phase 2b registrational study of SkinJect®, a microneedle patch delivering doxorubicin directly into basal cell carcinoma lesions, for patients with Gorlin Syndrome. Backed by strong Phase 2 clearance data, SkinJect® could become the first FDA-approved lesion-directed therapy for this rare, tumor-prone patient population. Read More >
Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH
The FDA has granted Orphan Drug Designation to Inhibikase Therapeutics’ IKT-001, a once-daily oral prodrug of imatinib being developed for Pulmonary Arterial Hypertension, a progressive disease affecting roughly 50,000 Americans. The designation brings tax credits, fee exemptions, and up to seven years of market exclusivity, as IKT-001 advances through its Phase 3 IMPROVE-PAH trial. Read More >
Verismo Therapeutics Expands KIR-CAR Solid Tumor Treatment Pipeline with Novel Binder Developed at Penn Targeting Claudin 6 (CLDN6)
Verismo Therapeutics is expanding its multi-chain KIR-CAR pipeline with a new preclinical program targeting Claudin 6, a clinically validated solid tumor antigen, using a novel binder discovered through a sponsored research collaboration with Penn’s Perelman School of Medicine. The program complements Verismo’s lead mesothelin-targeting candidate SynKIR™-110, already in Phase 1 trials, reinforcing the region’s growing cell therapy footprint. Read More >
Inizio Engage Wants to Turn Medical Information Into a Strategy Tool, Not Just a Help Desk
Inizio Engage has launched Connected Insights, an AI-enabled expansion of its Global Medical Information platform that turns over one million annual scientific interactions across 500+ products into actionable intelligence for pharma and biotech clients. The expansion pairs deeper APAC infrastructure with AI-powered training, speech analytics, and virtual agents to help clients move Medical Information from reactive support into a strategic driver of Medical Affairs decisions. Read More >
Ecosystem
The partnerships, programs, and policy moves building Greater Philadelphia’s life sciences infrastructure — and the organizations driving it forward.
The $125 million Innovate in PA 2.0 initiative aims to help startups grow, commercialize new technologies and keep life sciences companies in Pennsylvania
Pennsylvania Governor Josh Shapiro has launched Innovate in PA 2.0, a $125M initiative designed to help life sciences startups bridge the “valley of death” between scientific breakthrough and commercialization, funding capital access, clinical trial infrastructure, and workforce development. Industry leaders are calling it the state’s most significant life sciences commitment in nearly three decades. Read More >
Minaris Expands Its Apprentice.io Partnership, Bringing Digital Manufacturing to Its Philadelphia Headquarters
Minaris is rolling out Apprentice.io’s digital manufacturing platform to its Philadelphia headquarters, Munich, and Yokohama sites, building on a successful deployment at its Allendale, NJ facility. The expansion gives Minaris real-time, cross-site manufacturing visibility from day one at its home base, a strong signal for Philadelphia’s standing as one of the country’s leading cell and gene therapy hubs. Read More >
Science Center and Genentech Launch Genentech Scholars Program
The Science Center and Genentech, a member of the Roche Group, have launched the Genentech Scholars Program, a competitive grants initiative offering up to $25,000 over 12 months for rigorous health research aimed at publication, policy impact, or clinical decision-making. Researchers can apply through two tracks , Disease-State (spanning eight areas including Alzheimer’s, IBD, and women’s health) or Community & Public Health — with proposals due August 21, 2026. Apply Now >
Other [Good] Reads
Editor’s picks from across the web — the stories, videos, and podcasts shaping the conversation in PHL biotech and life sciences this week.
From Bench to Business: How PA’s Ecosystem Backs Life Sciences Founders
Michelle Cully (PA Department of Community and Economic Development) and Rebecca Grant (Philadelphia Department of Commerce) break down the deep bench of city and state resources fueling life sciences founders — from SBIR/STTR funding and Keystone Innovation Zones to the Philadelphia Small Business Catalyst Fund. The conversation makes the case that Pennsylvania’s life sciences strength runs statewide, spanning Philadelphia’s growing company-building momentum, Lehigh Valley manufacturing, and rural healthcare innovation. Watch Now >
On the Calendar
A few of the upcoming events, conferences, and networking opportunities across Greater Philadelphia’s life sciences ecosystem that you don’t want to miss.
LSC PHL Project Onramp Internship Showcase 2026
Wednesday, August 5 • 3 – 5 PM EDT • Philadelphia, PA
Donated by B+Labs | Register Now >
SPE Delaware Valley Chapter’s 34th Annual Symposium & Exhibition
Thursday, August 6 • 8 AM – 7PM EDT • Philadelphia, PA
Hosted by ISPE | Register Now >
Philadelphia Healthcare, Pharma & Business Networking Event
Friday, August 7 • 7 – 9 PM EDT • Philadelphia, PA
Hosted by SUM OF FIVE | Register Now >
Did we miss something!? Drop us a line →
Stay connected to BioHealth Capital Region life sciences.
🔍 Explore companies → · 💼 Browse jobs → · 📅 See events → · 📰 Read more →
Get the BioHealth Capital Region Roundup every Friday.
The week’s most important life sciences news from BioHealth Capital Region— delivered to your inbox.
